Welcome to our dedicated page for Cytokinetics news (Ticker: CYTK), a resource for investors and traders seeking the latest updates and insights on Cytokinetics stock.
Cytokinetics, Incorporated develops and commercializes muscle-directed cardiovascular medicines, led by MYQORZO® (aficamten), a cardiac myosin inhibitor approved in the U.S., Europe and China for adults with symptomatic obstructive hypertrophic cardiomyopathy. Company news regularly covers MYQORZO clinical data, launch activity, regulatory approvals and analyses from HCM studies including SEQUOIA-HCM, MAPLE-HCM, FOREST-HCM and ACACIA-HCM.
Recurring updates also address Cytokinetics’ pipeline in cardiac muscle dysfunction, including omecamtiv mecarbil for heart failure with severely reduced ejection fraction and ulacamten for heart failure with preserved ejection fraction. Financial releases and corporate announcements include product revenue, operating updates, shareholder voting matters, common stock offerings and other capital-structure developments.
Cytokinetics (Nasdaq: CYTK) granted equity awards on May 15, 2026 as material inducements to 8 new employees under Nasdaq Listing Rule 5635(c)(4).
- 20,807 stock options at a $75.85 exercise price, 10-year term, vesting over 4 years
- 13,793 RSUs vesting over 3 years
Cytokinetics (Nasdaq: CYTK) will host the third annual Contemporary Landscapes in Muscle Biology (CLIMB) symposium on May 29, 2026, from 8:00 AM to 5:00 PM PT at the Mission Bay Conference Center in San Francisco.
Registration is free but capacity-limited, with an online deadline of May 22, 2026. CLIMB 2026 features a keynote by James A. Spudich, PhD, and expert sessions on cardiac biology, skeletal muscle biology and emerging treatment modalities, including genetic medicines, RNA medicines and muscle preservation.
Cytokinetics (Nasdaq: CYTK) announced participation in the 2026 RBC Capital Markets Global Healthcare Conference. Company management will join a fireside chat on May 19, 2026 at 3:35 PM ET in New York.
A live webcast and 90-day replay will be available via the Cytokinetics Investors & Media website.
Cytokinetics (Nasdaq: CYTK) reported new MYQORZO (aficamten) data at ESC Heart Failure 2026 from Phase 3 SEQUOIA-HCM, MAPLE-HCM and FOREST-HCM, plus real-world studies.
Results describe improved exercise capacity vs metoprolol, favorable left atrial remodeling, and long-term safety with stable arrhythmia rates and durable LVOT gradient and biomarker reductions.
Cytokinetics (Nasdaq: CYTK) closed an underwritten public offering on May 8, 2026, selling 11,338,028 common shares (including full exercise of a 1,478,873-share option) at $71.00 per share for gross proceeds of approximately $805 million.
All shares were sold by Cytokinetics; gross proceeds are before underwriting discounts, commissions and offering expenses.
Cytokinetics (Nasdaq: CYTK) priced an underwritten public offering of 9,859,155 common shares at $71.00 per share, raising approximately $700 million in gross proceeds before fees. The offering is expected to close on May 8, 2026 and includes a 30‑day option to sell 1,478,873 additional shares.
All shares are being sold by Cytokinetics; joint book‑running managers include Morgan Stanley, Goldman Sachs, J.P. Morgan and Jefferies. The offering is made under a shelf registration effective February 27, 2025.
Cytokinetics (Nasdaq: CYTK) announced a proposed underwritten public offering of approximately $650 million of common stock, with an expected 30-day underwriter option to purchase up to an additional 15% of shares. All offered shares will be sold by Cytokinetics.
The offering is subject to market and other conditions; a preliminary prospectus supplement will be filed with the SEC and will be publicly available.
Cytokinetics (NASDAQ: CYTK) reported Q1 2026 results and a business update. Key items: U.S. launch of MYQORZO began Jan 27 with strong early demand, $4.8M net product revenue in ~9 weeks, ACACIA-HCM met dual primary endpoints in nHCM, European Commission approved MYQORZO for oHCM, and FDA set a PDUFA date of Nov 14, 2026 for MAPLE-HCM supplemental NDA.
Financials: ~$1.1B cash and investments as of Mar 31, 2026; Q1 net loss of $206.0M. Company maintained full-year GAAP combined R&D and SG&A guidance of $830M–$870M.
Cytokinetics (Nasdaq: CYTK) announced positive topline results from ACACIA-HCM, a pivotal Phase 3 trial of aficamten in symptomatic non‑obstructive hypertrophic cardiomyopathy. The trial met both dual primary endpoints: KCCQ‑CSS (LSM diff 3.0; p=0.021) and pVO2 (LSM diff 0.67 mL/kg/min; p=0.003) at Week 36.
Key secondary endpoints improved (NYHA class, composite ventilatory efficiency/pVO2, NT‑proBNP). No new safety signals; LVEF 50% occurred in 10% on aficamten versus 1% on placebo.
Cytokinetics (NASDAQ: CYTK) will announce topline results from ACACIA-HCM on May 5, 2026.
The company will host a conference call and simultaneous webcast on Tuesday, May 5 at 8:00 AM Eastern Time. An archived replay will be available on the investor website for six months.